[DOI] [PubMed] [Google Scholar] 48.Beckett GJ, Chapman BJ, Dyson EH, Hayes JD
thch Thy Dung mua ti rocy.vn c xp hng 5 5 sao Gi tt, c qu tng, kh thch
The compound has never received market authorization in Canada or anywhere else, and Metabolic Pharmaceuticals terminated clinical development in 2007 after the Phase IIb obesity trial failed
A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer
Cd concentration in the renal tissue and absolute kidney weight of the Cd-treated mice were significantly higher than those of control group
These small-sized liposomes allow for increased absorption and diffusion across mucus membranes